摘要
羟甲戊二酰辅酶A(HMG—CoA)还原酶抑制剂类血脂调节药，又称“他汀类”调脂药，是近年全球最为热销的类别，国外阿伐他汀、辛伐他汀、普伐他汀都进入单品种销售额领先前20种药品。随着人类疾病结构的改变，由高血脂症引发的疾病成为威胁健康的劲敌。因此调血脂药成为医药市场最受关注的药品。
同被引文献24
-
1Ratz Bravo AE,Tchambaz L,Krahenbuhl-Meicher A,et al.Prevalence of potentially severe drug-drug interactiond in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.Drug Saf,2005,28(3):263
-
2Koh KK,Quon MJ,Han SH,et al.Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic.hypertensive patients.Circulation,2004,110(24):3687
-
3Nishio S,Watanabe H,Kosuge K,et al.Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension.Hypertens Res,2005,28(3)223
-
4Ziviani L,Da Ros L,Squassante L,et al.The effects of lacididipine on the steady/state plasma concentrations of simvastatin in healthy subjects.Br J Clin Pharmacol,2001,51(2)147
-
5Georg Nickenig,MD.Should Angiotensin Ⅱ Receptor Blockers and Statins Be Combined? Circulation,2004.110
-
6Bovd Ra,Stem RH,Stewart BH,et al.Atorvastatin coadministration may increase Digoxin concentrations by inhibition of intestinal P-glycoprotein-mediate secretion.J Clin Pharmacol,2000,40(1):91
-
7Weber P,Lettieri Jt,Kaiser L,et al.Lack of mutual pharmacokinetic interaction between cervastatin,a new LMG-CoA reductase inhibitor,and digoxin in healthy normocholesterolemic volunteers.Clin Ther,1999,21(9):1563
-
8Triscari J,Squibb Bn,Willard DA,et al.steady state serum concentrations of pravastatin and digoxin when given in combination.Br J Clin Pharmacol,1993,36(3):263
-
9Kantola T,Kivisto Kt,Neuvonen PJ.Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.Clin pharmacol Ther,1999,65(5):583
-
10Schmassmann-Suhijar D,Bullingham R,Gasser R,et al.Rhabdomyolysis due to interaction of simvastatin with mibefradil.Lancet,1998,351:1929
二级引证文献6
-
1徐少俊.他汀类与心血管药物配伍安全性分析[J].现代养生,2014,0(20):48-48.
-
2冯现俊.他汀类与心血管药物配伍的疗效观察及安全分析[J].中国医药指南,2013,11(10):620-621. 被引量：3
-
3钱冬平.他汀类与心血管药物配伍安全性分析[J].心血管病防治知识（学术版）,2014,4(8):75-76. 被引量：3
-
4涂学龄.他汀类药物与心血管药物配伍的安全性系统评价[J].北方药学,2015,12(10):120-121. 被引量：6
-
5魏远明.我院他汀类降血脂药物的使用情况和处方分析[J].海峡药学,2016,28(12):259-260. 被引量：5
-
6郑雄伟,姜志华.银杏叶提取物注射液联合依达拉奉治疗急性腔隙性脑梗死效果观察[J].临床合理用药杂志,2018,11(13):77-80. 被引量：10
-
1任吉民,张立.他汀类降脂药物市场浅析[J].上海医药,2005,26(7):313-314. 被引量：5
-
2刘国良,赵晓娟,都建,王秋月,张静,郑晓敏,曹翠平,任路平.糖适平治疗2型糖尿病的临床疗效观察[J].辽宁实用糖尿病杂志,2004,12(3):58-60. 被引量：10
-
3杜晓红,陈素秀,蒋亦燕.氯沙坦对老年高血压患者血尿酸和血脂的影响[J].国外医学（心血管疾病分册）,2001,28(6):360-361. 被引量：4
-
4祖玉梅,张立军.102例抗菌药物不良反应分析[J].中国实用医药,2010,5(24):131-132. 被引量：4
-
5徐武华,陈坚,邓哲彤.醋柳黄酮与依那普利治疗高血压的临床对照研究[J].中国综合临床,2001,17(12):902-903. 被引量：3
-
6高宏科.羟甲戊二酰辅酶A还原酶抑制剂的药理作用及临床应用[J].新医学,1996,27(8):432-434.
-
7赵旺,赵水平.他汀类药物引发糖尿病的机制[J].中南药学,2013,11(1):47-49. 被引量：5
-
8王向红.浅谈他汀类药物对机体糖代谢的影响[J].当代医药论丛,2015,13(6):12-14.
-
9陈碧珊,苏丽华.他汀类药物的研究进展[J].中国药房,2005,16(7):545-546. 被引量：57
-
10翟凤莉,翟凤艳,崔英.他汀类药物的临床应用及不良反应[J].中国民康医学,2007,19(14):575-576. 被引量：2
